Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Clinical and Molecular Comparative Analysis of KRAS Exon 2 and KRAS Non-Exon 2 Mutated Colorectal Cancer.

Cancers·2026
Same author

Immune Checkpoint Inhibitor Outcomes Across Child-Pugh A, B, and C Hepatocellular Carcinoma: A Real-World Integrated Health-System Cohort.

Cancer treatment and research communications·2026
Same author

Knowledge-guided contextual gene set analysis with large language models.

Bioinformatics (Oxford, England)·2026
Same author

mTORC1 suppression by Trp53 mutation drives resistance to immune checkpoint blockade.

Cell death & disease·2026
Same author

EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.

Future oncology (London, England)·2026
Same author

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal of hepatology·2026

Related Experiment Video

Updated: Jun 4, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

Current transcriptome database and biomarker discovery for immunotherapy by immune checkpoint blockade.

Han Zhang, Binfeng Lu, Xinghua Lu

    Biorxiv : the Preprint Server for Biology
    |December 23, 2024
    PubMed
    Summary

    Predicting response to immune checkpoint blockade (ICB) therapy is crucial. This review explores biomarkers for ICB, compares databases, and introduces IOhub for analysis, aiding precision immuno-oncology.

    More Related Videos

    Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
    09:40

    Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

    Published on: August 2, 2024

    2.6K
    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
    06:07

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

    Published on: February 5, 2020

    5.7K

    Related Experiment Videos

    Last Updated: Jun 4, 2025

    Predictive Immune Modeling of Solid Tumors
    08:50

    Predictive Immune Modeling of Solid Tumors

    Published on: February 25, 2020

    6.9K
    Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
    09:40

    Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

    Published on: August 2, 2024

    2.6K
    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
    06:07

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

    Published on: February 5, 2020

    5.7K

    Area of Science:

    • Oncology
    • Immunology
    • Bioinformatics

    Background:

    • Immune checkpoint blockade (ICB) has transformed cancer treatment, but response rates remain limited.
    • Identifying patients who will benefit from ICB is essential for effective clinical application.

    Purpose of the Study:

    • To review current biomarkers for predicting ICB response.
    • To compare existing databases for biomarker discovery.
    • To introduce IOhub, a web portal for analyzing ICB biomarkers.

    Main Methods:

    • Literature review of biomarkers focusing on tumor genome, microenvironment, and host interactions.
    • Comparative analysis of existing biomarker discovery databases.
    • Development and presentation of the IOhub web portal with integrated transcriptome datasets.

    Main Results:

    • Discussion of diverse biomarkers for ICB response prediction.
    • Evaluation of current databases and their utility in biomarker discovery.
    • IOhub provides a platform for benchmark analysis of biomarkers using 36 bulk and 10 single-cell transcriptome datasets.

    Conclusions:

    • Robust predictive biomarkers are critical for optimizing ICB therapy.
    • IOhub serves as a valuable resource for evaluating and advancing ICB biomarkers.
    • Future directions include antibody drug conjugates and combination therapies for precision immuno-oncology.